Gemini Therapeutics

Disc Medicine, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development and commercialization of novel treatments for patients suffering from serious hematologic disorders. The company was founded in October 2017 and is headquartered in Watertown, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development, and commercialization of novel treatments for hematologic disorders. Its programs include Bitopertin, DISC-0974, and DISC-3405. The company was founded in October 2017 and is headquartered in Watertown, MA.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced a corporate restructuring, including several executive officer transitions, to prioritize assets and focus on initiating and executing GEM103's resource-intensive pivotal trial in geographic atrophy (GA). “Given the positive safety, biomarkers data, and pharmacokin

Gemini Therapeutics Announces Corporate Restructuring to Prioritize Late-Stage Clinical Development of GEM103 for Geographic Atrophy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced one oral presentation and the presentation of three posters at the 13th International Conference on Complement Therapeutics held in Ioannina, Greece from September 8-13, 2021. “The results presented today underscore the potential of GEM103 as the next class of comp

Gemini Therapeutics Announces Presentation of Preclinical Data at the 13th International Conference on Complement Therapeutics

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Raj Maturi, M.D., Adjunct Clinical Assistant Professor of Ophthalmology at Indiana University School of Medicine and an investigator in the ReGAtta study, presented Gemini's previously released initial results from its ongoing Phase 2a study at EURETINA 2021 V

Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at EURETINA 2021 Virtual

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Jason Meyeburg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in the H.C. Wainwright 23rd Annual Global Investment Conference. The presentation will be available on-demand starting at 7 AM ET on Monday, September 13, 202

Gemini Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

Investors need to pay close attention to Gemini Therapeutics (GMTX) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Gemini Therapeutics (GMTX) Stock?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Chief Executive Officer, Jason Meyenburg, and Chief Medical Officer, Samuel Barone, M.D., presented in panel discussions at the Clinical Trials at the Summit on August 28, 2021. As part of the panel discussions, which included: Concept to Concrete: Turning Ide

Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at Clinical Trials at the Summit

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today reported its financial results for the second quarter ended June 30, 2021 and provided a business update. “The initial results shared in June from the ongoing Phase 2a ReGAtta study in patients with geographic atrophy showed biomarker results that support the biological acti

Gemini Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Jason Meyeburg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in the H.C. Wainwright Ophthalmology Conference on Tuesday, August 17 at 9:00 AM ET. A live webcast of the event will be available on the "Events & Presen

Gemini Therapeutics to Participate in the H.C. Wainwright Ophthalmology Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced initial data from its Phase 2a ReGAtta study of GEM103 as of May 2021 in patients with geographic atrophy (GA) secondary to dry AMD. ReGAtta is a dose escalation trial of GEM103, which is intravitreally administered recombinant human complement factor H (CFH), in dr

Gemini Therapeutics Announces Initial Data From Its Ongoing Phase 2a Study of GEM103 in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Corbus Pharmaceuticals Holdings

Intellia Therapeutics

Important events on the horizon could push these biotech stocks higher or press them further into the dirt.

3 Biotech Stocks With Big Catalysts in June

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Jason Meyenburg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in the Jefferies Virtual Healthcare Conference on Wednesday, June 2 at 3:30 PM ET. A live webcast of the event will be available on the "Events & Present

Gemini Therapeutics to Participate in the Jefferies Virtual Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today reported its financial results for the first quarter ended March 31, 2021 and provided a business update. “During the first quarter, we continued to make significant progress in the clinical development of GEM103 and look forward to releasing initial data from the ongoing Ph

Gemini Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced the completion of enrollment in its Phase 2a trial advancing GEM103 as a potential add-on therapy for patients suffering from wet AMD and requiring continued anti-vascular endothelial growth factor (anti-VEGF) treatment who have, or may be at risk for, macular atro

Gemini Therapeutics Completes Enrollment in Phase 2a Study of GEM103 as an Add-On to Anti-VEGF Therapy for the Treatment of Wet AMD Patients at Risk for Progressive Vision Loss Due to Macular Atrophy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced the appointment of Georges Gemayel, Ph. D., as the Chair of the Company's Board of Directors. “I am pleased to welcome Georges to Gemini's Board of Directors during this important time in our Company's maturation, as we advance our lead

Gemini Therapeutics Announces Appointment of Georges Gemayel, Ph.D. as Chair of Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced the presentation of preclinical data at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Virtual Annual Meeting, held May 1 to 7, 2021. The poster, titled “Anti-angiogenic activity of Complement Factor H in a laser-in

Gemini Therapeutics Announces Presentation of Preclinical Data at 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced the grant of an inducement award to Brian Piekos, Gemini's Chief Financial Officer and the grant of an inducement award to Dr. Sam Barone, Gemini's Chief Medical Officer. In accordance with NASDAQ Listing Rule 5635(c)(4), the award was approved by Gemini's Compensa

Gemini Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced the appointment of Samuel Barone, M.D., as Gemini's Chief Medical Officer, effective immediately. “We are thrilled to welcome Sam to Gemini as Chief Medical Officer, where he will bring his expertise as a board-certified ophthalmologist

Gemini Therapeutics Appoints Samuel Barone, M.D., as Chief Medical Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today reported its financial results for the year ended December 31, 2020 and provided a business update. “The past 12 months have been truly transformative for Gemini as we successfully transitioned to a publicly traded precision medicine company with a strong balance sheet and r

Gemini Therapeutics Reports Full Year 2020 Financial Results and Provides Business Update

Gemini Therapeutics is bringing precision medicine and genomics to Dry AMD, a disease without an FDA-approved medicine. By focusing on CFH variants of Dry AMD, which represent over 6M patients in the US, the company is the first to bring a recombinant CFH into the clinic.

Gemini Therapeutics: Precision Medicine Company Focused On Dry AMD

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced that Jason Meyeburg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in the SVB Leerink 10th Annual Global Healthcare Conference on Thursday, February 25 at 1:00 PM ET. A live webcast of the event wi

Gemini Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference

AppHarvest

Hims & Hers Health

SPACs dominated Wall Street in 2020. The backwards IPOs of these three companies suggests that 2021 will be more of the same.

3 of the Latest Companies to Go Public Via SPACs

Gemini Therapeutics Inc (NASDAQ: GMTX) concludes enrollment in its Phase 2a ReGAtta study evaluating GEM103, a recombinant human complement factor H (CFH), in dry Age-related macular degeneration (AMD) patients with CFH loss-of-function gene variants. The 60-subject trial is designed to evaluate safety and tolerability and measures of intraocular pharmacokinetics (PK) and disease-relevant biomarkers.

Gemini Therapeutics Completes 60 Patients Enrollment In Lead Candidate Mid-Stage Study In Dry AMD

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced the completion of enrollment in its Phase 2a “ReGAtta” study. ReGAtta is a dose escalation trial of GEM103, a recombinant human complement factor H (CFH), in dry AMD patients with CFH loss-of-function gene variants. The trial is designed

Gemini Therapeutics Completes Enrollment in Phase 2a Trial of GEM103 in Dry Age-Related Macular Degeneration (AMD) in Patients with High-Risk Genetic Variants

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc., (Nasdaq: GMTX) a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Brian Piekos has been appointed to serve as Chief Financial Officer. Mr. Piekos brings more than 20 years of experience in industry and finance to Gemini. “It is my pleasure to welcome Brian to the team at this exciting time in Gemini's history right on the he

News for Gemini Therapeutics Stock (GMTX)